Kfh - Oakland
- Type
- Teaching hospital
- Where
- Oakland, CA
- Medicare CCN
- 050075
- Received
- $7,239,458 in 472 records, 2020 ($1,416 general, $7,238,042 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 5 | $1,416 |
| 2020 | Research payment | 467 | $7,238,042 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Merck Sharp & Dohme LLC | 255 | $3,010,394 | 2020 |
| Gilead Sciences, Inc. | 110 | $2,579,649 | 2020 |
| Amarin Pharma, Inc. | 3 | $635,477 | 2020 |
| SEAGEN INC. | 20 | $291,408 | 2020 |
| Edwards Lifesciences Corporation | 13 | $219,571 | 2020 |
| Novartis Pharmaceuticals Corporation | 1 | $187,183 | 2020 |
| Nevro Corp. | 5 | $64,758 | 2020 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $44,407 | 2020 |
| E.R. Squibb & Sons, L.L.C. | 6 | $39,600 | 2020 |
| PUMA BIOTECHNOLOGY, INC. | 4 | $37,708 | 2020 |
| Novocure Inc. | 9 | $36,701 | 2020 |
| Janssen Scientific Affairs, LLC | 1 | $31,011 | 2020 |
| Intercept Pharmaceuticals, Inc. | 7 | $22,921 | 2020 |
| Surgalign Spine Technologies, Inc. | 2 | $14,878 | 2020 |
| Alnylam Pharmaceuticals Inc. | 3 | $9,180 | 2020 |
| Amgen Inc. | 1 | $7,421 | 2020 |
| MDD US Operations, LLC | 13 | $5,409 | 2020 |
| Mindray DS USA, Inc. | 1 | $908 | 2020 |
| Cochlear Americas | 4 | $508 | 2020 |
| VIVUS LLC | 2 | $360 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 467 | $7,238,042 |
| Education | 1 | $908 |
| Grant | 4 | $508 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Mindray DS USA, Inc. | $908 | Education | In-kind items and services | Accutorr 7, Masimo, CO2, temp, 2.4/5GHz Device, Monitoring Equipment | 2020 | |
| 2020-12-29 | Merck Sharp & Dohme LLC | $83,870 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-12-23 | Edwards Lifesciences Corporation | $15,318 | Research payment | Cash or cash equivalent | CLASP IIF (2018-07) | 2020 | |
| 2020-12-23 | Gilead Sciences, Inc. | $6,450 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $5,250 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $3,351 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $1,312 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $1,312 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $1,117 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita | 2020 |
| 2020-12-21 | Edwards Lifesciences Corporation | $30,711 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2020 | |
| 2020-12-18 | Novocure Inc. | $6,046 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-25 Pivotal, oopen-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 | 2020 |
| 2020-12-18 | Novocure Inc. | $4,651 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-25 Pivotal, oopen-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 | 2020 |
| 2020-12-18 | Takeda Pharmaceuticals U.S.A., Inc. | $164 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS | 2020 | |
| 2020-12-17 | Edwards Lifesciences Corporation | $7,164 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2020 | |
| 2020-12-15 | Takeda Pharmaceuticals U.S.A., Inc. | $6,500 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS | 2020 | |
| 2020-12-15 | Takeda Pharmaceuticals U.S.A., Inc. | $6,500 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS | 2020 | |
| 2020-12-09 | SEAGEN INC. | $11,179 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | $141 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | $132 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | $36 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | $36 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | $36 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | $36 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | $28 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | $11 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-12-08 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-12-03 | Novocure Inc. | $17,375 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-25 Pivotal, oopen-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 | 2020 |
| 2020-12-03 | E.R. Squibb & Sons, L.L.C. | $17,275 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III Adjuvant Melanoma Stage II B C Opdivo Mono | 2020 |
| 2020-12-03 | Merck Sharp & Dohme LLC | $3,771 | Research payment | Cash or cash equivalent | DELSTRIGO Drug, INFECTIOUS DISEASE | A Phase III Multicenter, Open-Label, Randomized, Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virol | 2020 |
| 2020-12-03 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-12-02 | Gilead Sciences, Inc. | $13,797 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | Phase 3 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734) tre | 2020 |
| 2020-12-01 | Merck Sharp & Dohme LLC | $65,542 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-11-30 | Merck Sharp & Dohme LLC | $469 | Research payment | Cash or cash equivalent | DELSTRIGO Drug, INFECTIOUS DISEASE | A Phase III Multicenter, Open-Label, Randomized, Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virol | 2020 |
| 2020-11-25 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-23 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-23 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-18 | Gilead Sciences, Inc. | $10,496 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-11-18 | Gilead Sciences, Inc. | $4,112 | Research payment | Cash or cash equivalent | Descovy Drug, HIV | A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide | 2020 |
| 2020-11-18 | Gilead Sciences, Inc. | $2,624 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-11-18 | Gilead Sciences, Inc. | $2,234 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita | 2020 |
| 2020-11-18 | Gilead Sciences, Inc. | $2,056 | Research payment | Cash or cash equivalent | Descovy Drug, HIV | A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide | 2020 |
| 2020-11-18 | Gilead Sciences, Inc. | $1,312 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-11-18 | Gilead Sciences, Inc. | $1,117 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita | 2020 |
| 2020-11-16 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-16 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-12 | Novocure Inc. | $2,410 | Research payment | Cash or cash equivalent | Optune Device, Oncology | EF-25 Pivotal, oopen-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 | 2020 |
| 2020-11-11 | PUMA BIOTECHNOLOGY, INC. | $21,039 | Research payment | Cash or cash equivalent | NERLYNX Drug, ONCOLOGY | THIS IS AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, MULTINATIONAL, PHASE 2 STUDY | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $36 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $36 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $36 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $36 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $31 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $31 | Research payment | In-kind items and services | MK-7339 Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2020 |
| 2020-11-09 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2020 |
| 2020-11-05 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-04 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-10-30 | Merck Sharp & Dohme LLC | $1,080 | Research payment | Cash or cash equivalent | DELSTRIGO Drug, INFECTIOUS DISEASE | A Phase III Multicenter, Open-Label, Randomized, Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virol | 2020 |
| 2020-10-30 | Merck Sharp & Dohme LLC | $610 | Research payment | Cash or cash equivalent | DELSTRIGO Drug, INFECTIOUS DISEASE | A Phase III Multicenter, Open-Label, Randomized, Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virol | 2020 |
| 2020-10-29 | Merck Sharp & Dohme LLC | $65,139 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-10-29 | Nevro Corp. | $20,300 | Research payment | Cash or cash equivalent | Senza Spinal Cord Stimulation System Device, Spinal Cord Stimulator | Post Market Study | 2020 |
| 2020-10-28 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-10-28 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-10-26 | Edwards Lifesciences Corporation | $14,120 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2020 | |
| 2020-10-22 | Edwards Lifesciences Corporation | $260 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2020 | |
| 2020-10-21 | Gilead Sciences, Inc. | $31,485 | Research payment | Cash or cash equivalent | Descovy Drug, HIV | A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide | 2020 |
| 2020-10-21 | Gilead Sciences, Inc. | $4,670 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of FTC/TAF and | 2020 |
| 2020-10-21 | Gilead Sciences, Inc. | $2,056 | Research payment | Cash or cash equivalent | Descovy Drug, HIV | A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide | 2020 |
| 2020-10-20 | SEAGEN INC. | $5,000 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-10-20 | SEAGEN INC. | $3,675 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-10-20 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-10-17 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-10-17 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-10-14 | SEAGEN INC. | $10,091 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-10-12 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-10-05 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-10-05 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-10-01 | Novartis Pharmaceuticals Corporation | $187,183 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | RESEARCH RELATED TO ENTRESTO | 2020 |
| 2020-10-01 | Edwards Lifesciences Corporation | $5,549 | Research payment | Cash or cash equivalent | Partner3 2015-08 | 2020 | |
| 2020-09-29 | Merck Sharp & Dohme LLC | $1,080 | Research payment | Cash or cash equivalent | DELSTRIGO Drug, INFECTIOUS DISEASE | A Phase III Multicenter, Open-Label, Randomized, Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virol | 2020 |
| 2020-09-29 | Merck Sharp & Dohme LLC | $492 | Research payment | Cash or cash equivalent | DELSTRIGO Drug, INFECTIOUS DISEASE | A Phase III Multicenter, Open-Label, Randomized, Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virol | 2020 |
| 2020-09-24 | Amarin Pharma, Inc. | $500,000 | Research payment | Cash or cash equivalent | Vascepa Drug, Cardiovascular | A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults (MITIGATE) | 2020 |
| 2020-09-24 | Amarin Pharma, Inc. | $67,738 | Research payment | Cash or cash equivalent | Vascepa Drug, Cardiovascular | Residual Risk | 2020 |
| 2020-09-24 | Merck Sharp & Dohme LLC | $65,611 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-09-23 | Gilead Sciences, Inc. | $56,381 | Research payment | Cash or cash equivalent | Descovy Drug, HIV | A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide | 2020 |
| 2020-09-23 | Gilead Sciences, Inc. | $18,934 | Research payment | Cash or cash equivalent | Descovy Drug, HIV | A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide | 2020 |
| 2020-09-23 | Gilead Sciences, Inc. | $4,668 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-09-23 | Gilead Sciences, Inc. | $3,351 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita | 2020 |
| 2020-09-23 | Gilead Sciences, Inc. | $2,334 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-09-23 | Intercept Pharmaceuticals, Inc. | $1,952 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-09-23 | Gilead Sciences, Inc. | $1,167 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-09-23 | Gilead Sciences, Inc. | $1,117 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita | 2020 |
| 2020-09-21 | Merck Sharp & Dohme LLC | $500 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-09-18 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-09-18 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-09-17 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-09-17 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-09-14 | PUMA BIOTECHNOLOGY, INC. | $3,989 | Research payment | Cash or cash equivalent | NERLYNX Drug, ONCOLOGY | THIS IS AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, MULTINATIONAL, PHASE 2 STUDY | 2020 |
| 2020-09-08 | Takeda Pharmaceuticals U.S.A., Inc. | $1,200 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY COMPARING ORAL MLN9708 PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS | 2020 | |
| 2020-09-08 | Merck Sharp & Dohme LLC | $70 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $30 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $24 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $19 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $2 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2020 |
| 2020-09-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2020 |
| 2020-09-02 | Gilead Sciences, Inc. | $9,209 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-09-02 | Gilead Sciences, Inc. | $2,100 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-09-02 | SEAGEN INC. | $1,125 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-09-02 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-08-31 | Merck Sharp & Dohme LLC | $9,777 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety and Tolerabi | 2020 |
| 2020-08-31 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-08-31 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-08-27 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-08-27 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-08-25 | PUMA BIOTECHNOLOGY, INC. | $9,354 | Research payment | Cash or cash equivalent | NERLYNX Drug, ONCOLOGY | THIS IS AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, MULTINATIONAL, PHASE 2 STUDY | 2020 |
| 2020-08-25 | Merck Sharp & Dohme LLC | $1,080 | Research payment | Cash or cash equivalent | DELSTRIGO Drug, INFECTIOUS DISEASE | A Phase III Multicenter, Open-Label, Randomized, Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virol | 2020 |
| 2020-08-25 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-08-25 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-08-24 | Edwards Lifesciences Corporation | $21,021 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2020 | |
| 2020-08-20 | Merck Sharp & Dohme LLC | $79,154 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerabilit | 2020 |
| 2020-08-19 | Gilead Sciences, Inc. | $45,521 | Research payment | Cash or cash equivalent | Descovy Drug, HIV | A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide | 2020 |
| 2020-08-19 | Gilead Sciences, Inc. | $30,289 | Research payment | Cash or cash equivalent | Descovy Drug, HIV | A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide | 2020 |
| 2020-08-19 | SEAGEN INC. | $9,295 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2020 |
| 2020-08-19 | Intercept Pharmaceuticals, Inc. | $5,875 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-08-19 | Gilead Sciences, Inc. | $4,668 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-08-19 | Gilead Sciences, Inc. | $2,234 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita | 2020 |
| 2020-08-19 | Gilead Sciences, Inc. | $1,167 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-08-19 | Gilead Sciences, Inc. | $1,167 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafena | 2020 |
| 2020-08-19 | Gilead Sciences, Inc. | $1,117 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricita | 2020 |
| 2020-08-19 | Gilead Sciences, Inc. | $1,109 | Research payment | Cash or cash equivalent | Biktarvy Drug, HIV | A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Tra | 2020 |
| 2020-08-18 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-08-18 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-08-14 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-08-14 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-08-13 | Merck Sharp & Dohme LLC | $5,400 | Research payment | Cash or cash equivalent | V114 Biological, VACCINE | A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety and Tolerabi | 2020 |
| 2020-08-12 | Nevro Corp. | $18,654 | Research payment | Cash or cash equivalent | Senza Spinal Cord Stimulation System Device, Spinal Cord Stimulator | Post Market Study | 2020 |
The latest 200 records of 472.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Oakland, CA, county Alameda County, CA, state California; placed by its city name.
| Measure | Place (city or town) Oakland, CA | County Alameda County, CA | State California |
|---|---|---|---|
| Population B01003 | 439,418 | 1,649,473 | 39,287,377 |
| Population, 2020 census P1 | 440,646 | 1,682,353 | 39,538,223 |
| Median age B01002 | 37.9 | 39.0 | 37.9 |
| Under 18 B01001 | 18.9% | 19.8% | 22.0% |
| 65 and over B01001 | 14.7% | 15.4% | 15.7% |
| Households B11001 | 176,584 | 598,246 | 13,548,091 |
| Foreign born B05002 | 27.5% | 34.7% | 27.0% |
| Median household income B19013 | $101,600 | $129,367 | $99,122 |
| Median family income B19113 | $119,871 | $159,585 | $113,346 |
| Per capita income B19301 | $61,757 | $65,862 | $49,513 |
| Poverty rate B17001 | 13.4% | 9.2% | 12.0% |
| Unemployment rate B23025 | 6.4% | 5.4% | 6.6% |
| Civilian labor force B23025 | 250,892 | 908,995 | 20,068,466 |
| Mean commute (minutes) B08013 | 29.8 | 31.0 | 28.7 |
| Bachelor's degree or higher B15003 | 48.7% | 52.2% | 37.1% |
| Housing units B25001 | 191,713 | 637,212 | 14,644,735 |
| Owner-occupied B25003 | 42.3% | 54.4% | 55.9% |
| Renters B25003 | 57.7% | 45.6% | 44.1% |
| Median home value B25077 | $929,900 | $1,090,100 | $734,700 |
| Median gross rent B25064 | $1,979 | $2,357 | $2,036 |
| White, not Hispanic B03002 | 27.8% | 27.4% | 33.8% |
| Black B03002 | 19.7% | 9.3% | 5.2% |
| Hispanic or Latino B03002 | 28.7% | 23.4% | 40.2% |
| Asian B03002 | 15.7% | 32.7% | 15.3% |
| American Indian and Alaska Native B03002 | 0.3% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Oakland, CA.
Comments